ACC 2023: SGLT2i Use - Dos and Don'ts

ACC 2023 Conference Coverage

A. Armbruster

Coronary CTA for Assessing CAD - Are We There Yet?

Matthew Budoff

SURPASS 2: Tirzepatide Versus Once-Weekly Semaglutide

Juan Frias

Evidence that Obesity and Diabetes are Driven by a Diet-Induced Biol…

University of Colorado Department of Medicine

R. Johnson

Weightloss in Menopause

Susan Brian

The Deadly Paradox: Current Practice, Driven by Guidelines, Is Not A…

Michael Makover

SGLT2 Inhibition in 2024: Use in Heart Failure and Mechanism of Acti…

28th Annual Heart Failure 2024: An Update on Therapy

M. Packer

The Differences Between the Products of GLP1's and GLP/GIPs

Susan Brian

Discussing Retatrutide: A GIP, GLP-1, and Glucagon Receptor Agonist

Susan Brian

Exercise, Weight Loss, and Breast Cancer Risk: The Importance of BMI

Cleveland Clinic Taussig Cancer Institute

A. Guthrie

Vitamin D Deficiency

Keck School of Medicine of USC

V. Gevorgyan

Cholesterol Treatment Decisions: Recent Updates to Guidelines and St…

Gary Martin

ACC 2024 Insights: A Plant-Based Diet

ACC 2024 Insights

N. Barnard

Endoscopic Weight Loss Therapies - A Paradigm Shift in the Treatment…

Houston Methodist

T. R. Mccarty

Switch, Change, Rearrange: Diabetes Medication Transitions, De-presc…

Jennifer Rosselli

S. Twillmann

Could It Be Cushing’s? Rethinking Diabetes Management with the CATAL…

Robert Busch

Should I Use a Continuous Glucose Monitor, Even if I'm Healthy?

Integrative Medicine - Astrid Pujari

A. Pujari

The Best of AHA23 for the Primary Care Doctor

Cecilia Bahit

Obesity and Heart Health: Weighing the Facts

The North American Thrombosis Forum (NATF)

K. D. Palmer Emrich

New Research: Side Effect of GLP1

Susan Brian